High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Heine, Markus ^a   Freund, Barbara ^a   Nielsen, Peter ^a   Jung, Caroline ^a   Reimer, Rudolph ^b   Hohenberg, Heinrich ^b   Zangemeister Wittke, Uwe ^c   Wester, Hans Juergen ^d   Lüers, Georg H ^a   Schumacher, Udo ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; CANCER ANTIBODY; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; EPITHELIUM CELL; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN METABOLISM; QUANTITATIVE ANALYSIS; TISSUE PRESSURE; TRANSGENIC MOUSE; TUMOR XENOGRAFT; XENOTRANSPLANTATION; ANIMAL; CANCER TRANSPLANTATION; CELL STRAIN CACO 2; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESSURE; RADIOGRAPHY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BINDING SITES; CACO-2 CELLS; CELL ADHESION MOLECULES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; PRESSURE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84860693680     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036258     Document Type: Article

References (34)

1. Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, et al. (2008) In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol 26: 83-90.
2. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV, (2003) The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 163: 2139-2148.
3. Momburg F, Moldenhauer G, Hammerling GJ, Moller P, (1987) Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 47: 2883-2891.
4. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, et al. (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818-5824.
5. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, et al. (2004) High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86: 207-213.
6. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, et al. (2008) Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 61: 31-35.
7. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, et al. (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94: 128-135.
8. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G, (2000) Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356: 1981-1982.
9. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, et al. (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10: 3131-3136.
10. Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbersdobler A, et al. (2006) Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 6: 165.
11. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, et al. (2004) Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10: 2659-2669.
12. Akita H, Nagano H, Takeda Y, Eguchi H, Wada H, et al. (2011) Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Oncogene 30: 3468-3476.
13. Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, et al. (1982) Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1: 762-765.
14. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, et al. (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343: 1177-1183.
15. Hall MA, Kwon S, Robinson H, Lachance PA, Azhdarinia A, et al. (2011) Imaging prostate cancer lymph node metastases with a multimodality contrast agent. Prostate.
16. Thurber GM, Figueiredo JL, Weissleder R, (2010) Detection limits of intraoperative near infrared imaging for tumor resection. J Surg Oncol 102: 758-764.
17. Andratschke M, Gildehaus FJ, Johannson V, Schmitt B, Mack B, et al. (2007) Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody. Anticancer Res 27: 431-436.
18. Kosterink JG, McLaughlin PM, Lub-de Hooge MN, Hendrikse HH, van Zanten J, et al. (2007) Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model. J Immunol 179: 1362-1368.
19. Heldin CH, Rubin K, Pietras K, Ostman A, (2004) High interstitial fluid pressure- an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
20. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK, (2011) Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies. Annual Review of Chemical and Biomolecular Engineering 2: 281-298.
21. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ, (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A 73: 3278-3282.
22. Fodstad O, Kjonniksen I, Aamdal S, Nesland JM, Boyd MR, et al. (1988) Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res 48: 4382-4388.
23. Lange A, Gustke H, Glassmeier G, Heine M, Zangemeister-Wittke U, et al. (2011) Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro. Lung Cancer 74: 178-187.
24. Heine M, Nollau P, Masslo C, Nielsen P, Freund B, et al. (2011) Investigations on the Usefulness of CEACAMs as Potential Imaging Targets for Molecular Imaging Purposes. PLoS One 6: e28030.
25. Li Y, Song Y, Zhao L, Gaidosh G, Laties AM, et al. (2008) Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye DiI. Nat Protoc 3: 1703-1708.
26. Fadnes HO, Reed RK, Aukland K, (1977) Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 14: 27-36.
27. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK, (1991) Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51: 6691-6694.
28. Fernsten PD, Pekny KW, Reisfeld RA, Walker LE, (1990) Biosynthesis and glycosylation of the carcinoma-associated antigen recognized by monoclonal antibody KS1/4. Cancer Res 50: 4656-4663.
29. de Jonge MW, Kosterink JG, Bin YY, Bulte JW, Kengen RA, et al. (1993) Radioimmunodetection of human small cell lung carcinoma xenografts in the nude rat using 111in-labelled monoclonal antibody MOC-31. Eur J Cancer 29A: 1885-1890.
30. Lee C, Etchegaray JP, Cagampang FR, Loudon AS, Reppert SM, (2001) Posttranslational mechanisms regulate the mammalian circadian clock. Cell 107: 855-867.
31. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, et al. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731-3736.
32. Boucher Y, Salehi H, Witwer B, Harsh GR, Jain RK, (1997) Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer 75: 829-836.
33. Klosowska-Wardega A, Hasumi Y, Burmakin M, Ahgren A, Stuhr L, et al. (2009) Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One 4: e8149.
34. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, et al. (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071-1121.